1st Annual conference report, Badalona, Spain

1st Annual conference report, Badalona, Spain

Share this post

Facebook
Twitter
LinkedIn
WhatsApp

The hybrid conference titled “Exploring the Frontiers of Cancer Immunotherapy: From Models to Breakthroughs” took place on June 1 and 2 at the Josep Carreras Leukaemia Research Institute in Badalona (Barcelona, Spain). The event attracted a total 100 in-person and 80 virtual participants on the first day, and 80 in-person and 50 virtual attendees on the second day.

The conference aimed to spotlight novel experimental models that bridge laboratory discoveries on immunotherapy research with clinical breakthroughs. The meeting provided a platform to explore a diverse array of experimental models encompassing in vitro, ex vivo, and in vivo approaches, which offer unique opportunities to delve into the intricate interplay between the immune system, tumour microenvironment, and immunotherapy interventions in a controlled and clinically relevant context.

The conference featured six distinguished invited speakers, including renowned figures in the field of immunotherapy such as David Barbie and Silvia Formenti. Their expertise illuminated the latest advancements and future directions in cancer immunotherapy. Moreover, the event showcased the work of other participating researchers through nine selected abstracts for oral presentation and sixteen for poster presentation. This provided a forum for attendees to exchange insights, discuss challenges, and explore innovative strategies for advancing immunotherapy research.

Notably, 49 attendees received travel support attend the conference, underscoring IMMUNO-model’s commitment to facilitating broader participation and knowledge exchange within the scientific community.

In summary, the 1st IMMUNO-model conference served as a dynamic platform for advancing the frontiers of cancer immunotherapy, bringing together diverse perspectives and expertise to drive meaningful progress in the fight against cancer.

Latest Updates

Bridging Drug Delivery and Tumor Immunology: A Multidisciplinary Approach to Cancer Therapies Ebru Nur AY,Assistant Professor of Dept. of Molecular Biology and GeneticsIstinye University, Istanbul, Türkiye
🚀 Exciting News from working group 4 of IMMUNO-model! 🧬 We’re proud to announce the publication of four comprehensive review articles from Working Group 4, supported by the IMMUNO-model project! These articles explore key advancements in Cancer...
Published in Immunotherapy Advances (Official Journal of the British Society for Immunology) We invite submissions to a special collection on Imaging in Immunotherapy, guest edited by Dr Doreen Lau (Co-Leader, IMMUNO-model WG2)....
Nuno Rodrigues dos Santos (i3S, University of Porto) I acknowledge that I am aware that my data and dissemination material will be collected, stored, processed and used for the purposes...
You are kindly invited to the 9th IMMUNO-model webinar entitled “Turning Collaboration into Funding: MSCA Doctoral Network Success from IMMUNO-model to ACHILLES” that will be streamed live on the ZOOM platform on July...
We are excited to advertise the upcoming CAJAL Advanced Course in Cancer Neuroscience, taking place from 22 September to 10 October 2025 at the Bordeaux School of Neuroscience, France. This...

Join us

How to Participate

The COST Action IMMUNO-model welcomes research-active scientists working in the field.

How to Get Involved

  • Read the Project Description MoU;
  •  Inform the Main Proposer/Chair of your interest (email);
  • Apply to join your Working Groups of interest;
  • You will be informed by the working group leaders as soon as your application has been reviewed;
  • Please note, Management Committee nominations are carried out through the COST National Contact Points.

How to participate in an existing Action?

If you would like to join this COST Action please ensure that you read the guidance notes published on the COST website. You can find full documentation regarding general rules and guidelines for COST Actions at www.cost.eu/participate.

Subscribe to our newsletter